Group 1 - The company has been publishing an annual Social Responsibility Report since 2017 and will release its first ESG report in 2024 [2] - In 2023, the company established an ESG governance structure that operates from top to bottom, ensuring effective execution of ESG strategies [2] - The company aims to achieve EcoVadis Gold status for its longevity factory by 2025, emphasizing its commitment to sustainable development [2] Group 2 - The company is focusing on risk management and opportunities through ESG initiatives to promote sustainable and high-quality development [2] - The company is working on defining responsibilities, building organizational capabilities, and establishing incentive mechanisms to ensure the implementation of ESG goals [2]

Core Viewpoint - The company Tonghe Pharmaceutical has announced that its active pharmaceutical ingredient "Tafluprost" has received approval from the CDE, marking a significant milestone for its oral anticoagulant drug development [1] Group 1: Company Information - Tonghe Pharmaceutical (300636.SZ) has successfully submitted the active pharmaceutical ingredient "Tafluprost" for approval [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]

Core Viewpoint - Tonghua Shunhe Pharmaceutical has received approval from the CDE for its raw material drug "Tafluprost Tosylate," which is an oral anticoagulant used primarily for preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] Group 1 - The drug "Tafluprost Tosylate" is indicated for the prevention of strokes in non-valvular atrial fibrillation patients [1] - The drug is also used for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]

Group 1 - The pharmaceutical industry is experiencing continuous catalytic developments, with significant capital inflow into the Science and Technology Innovation Drug ETF (Guotai, 589720), which has seen nearly 1 billion yuan in net inflows over the past 20 days, indicating active capital positioning [1] - According to Zhongtai Securities, the raw material drug/intermediate industry has undergone 4-5 years of price decline, and with the rise in commodity and upstream chemical prices, a price improvement is expected. Most API product prices are at historical low levels, with limited profit margins and a low probability of further decline, showing a significant stabilization trend [1] - Innovative drug sectors such as small nucleic acids, peptides, and ADC toxins are continuously catalyzing the industry chain, contributing new business increments for raw material drug companies [1] Group 2 - The Science and Technology Innovation Drug ETF (Guotai, 589720) tracks the Science and Technology Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%. This index focuses on new drug research and development driven by technological innovation, covering companies in the biopharmaceutical and chemical pharmaceutical sectors with high R&D investment and innovation capabilities, reflecting the overall trend of innovation development in China's pharmaceutical industry, with a focus on growth style in its allocation [1]

Market Overview - The chemical pharmaceutical sector increased by 0.76% on February 4, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Gainers in Chemical Pharmaceutical Sector - Guangshantang (300436) closed at 116.01, up 7.50% with a trading volume of 144,300 shares and a transaction value of 16.55 billion [1] - Xinlitai (002294) closed at 48.15, up 4.27% with a trading volume of 118,000 shares and a transaction value of 564 million [1] - Zehao Pharmaceutical (688266) closed at 90.30, up 4.19% with a trading volume of 31,500 shares and a transaction value of 280 million [1] - Other notable gainers include Puluo Pharmaceutical (000739) and Shutaishen (300204), with increases of 4.17% and 4.14% respectively [1] Top Losers in Chemical Pharmaceutical Sector - Xinnoway (300765) closed at 35.80, down 3.79% with a trading volume of 126,300 shares [2] - Tonghua Jinma (000766) closed at 23.57, down 3.72% with a trading volume of 352,100 shares and a transaction value of 814 million [2] - Changshan Pharmaceutical (300255) closed at 48.63, down 3.09% with a trading volume of 246,200 shares and a transaction value of 1.186 billion [2] Capital Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 39.83 million from institutional investors, while retail investors experienced a net outflow of 190 million [2][3] - Notable net inflows from institutional investors include ST Renfu (600079) with 123 million and Guangshantang (300436) with 110 million [3] - Retail investors showed significant outflows from ST Renfu (600079) and Guangshantang (300436), with outflows of 71.99 million and 86.96 million respectively [3]

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 2.42% on February 2, 2025, underperforming the CSI 300 index by 0.29 percentage points, ranking 16th among 31 sub-industries [4]. - Key performers in the sector included hospitals (-0.99%), pharmaceutical distribution (-1.63%), and blood products (-1.65%), while other biopharmaceuticals (-3.69%) and offline pharmacies (-3.09%) lagged behind [4]. - Elevar has submitted a New Drug Application (NDA) to the FDA for Lirafugratinib, a selective oral FGFR2 inhibitor, showing a 46.5% objective response rate (ORR) in clinical trials for cholangiocarcinoma patients [5]. - The disease control rate for Lirafugratinib reached 96.5%, with a median progression-free survival (PFS) of 11.3 months and a median overall survival (OS) of 22.8 months [5]. - Jichuan Pharmaceutical has signed an exclusive commercialization agreement for a nasal spray in Greater China, with a payment of up to 100 million RMB [5]. - Heng Rui Pharmaceutical received FDA acceptance for its BLA submission for a combination therapy for liver cancer [6]. - Shanghai Yizhong reported a projected revenue of 317 million RMB for 2025, reflecting an 82.72% year-on-year growth [6]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3].

Core Viewpoint - The company has successfully completed the construction of a high-purity solvent project with an annual production capacity of 20,000 tons, which has effectively improved its capacity utilization rate [1] Group 1: Production and Capacity - The Changyi Tianyu project has officially commenced operations, leading to an increase in capacity utilization [1] - The company continues to solidify its position as a leading manufacturer of sartans, with a significant focus on the integration of raw materials and formulations [1] Group 2: Market Position and Revenue - The company's revenue from both raw materials and formulation products is showing a growth trend [1] - Several products have obtained CEP certification or are actively pursuing FDA certification, with revenue contributions expected to materialize as global market expansion progresses [1]

Market Performance - On February 4, A-shares showed mixed performance with the Shanghai Composite Index rising by 0.17% [1] - The ChiNext 50 Index fell by 1.90%, while the STAR 50 Index decreased by 2.14% [1] ETF Performance - The Huaxia STAR 100 ETF (588800.SH) experienced a decline of 1.71%, with a latest price of 1.495 [2] - The ETF has seen a net inflow of 0.27 billion CNY over the last five trading days and 1.34 billion CNY over the last ten days, with a total scale reaching 30.28 billion CNY [3] Sector Performance - Within the STAR 100 Index, the semiconductor sector dropped by 2.67%, while the battery sector saw a slight increase of 0.07% [3] - Other sectors such as chemical pharmaceuticals and communication equipment also experienced declines of 0.59% and 3.64%, respectively [3] Investment Insights - The STAR 100 Index is designed to track medium-sized, liquid stocks from the STAR Market, suitable for investors seeking long-term growth and willing to accept higher volatility [4]

Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical's stock performance and financing activities indicate a high level of market interest, despite a decline in revenue and profit [1][2]. - On February 3, Changshan Pharmaceutical's stock rose by 3.29%, with a trading volume of 868 million yuan, and a net financing buy of -5.88 million yuan, indicating a high financing balance of 2.508 billion yuan, which is 5.44% of its market capitalization [1]. - The company has a significant portion of its financing balance exceeding the 80th percentile over the past year, suggesting a high level of leverage in the market [1]. Group 2 - As of January 30, the number of shareholders in Changshan Pharmaceutical increased by 0.59% to 41,700, while the average number of circulating shares per person decreased by 0.59% to 22,018 shares [2]. - For the period from January to September 2025, Changshan Pharmaceutical reported a revenue of 681 million yuan, a year-on-year decrease of 13.11%, and a net profit attributable to shareholders of -44.82 million yuan, a decline of 714.77% [2]. - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.595 million yuan distributed in the last three years [3].

证券日报网讯 2月3日，艾迪药业在互动平台回答投资者提问时表示，公司股价波动受宏观经济、市场 环境、行业因素及投资者情绪等多重因素影响，具有不确定性。目前公司各项经营活动均正常开展，经 营基本面稳定，不存在应披露而未披露的重大事项。公司管理层始终致力于做好经营管理工作，持续提 升公司核心竞争力，努力为投资者创造长期价值。二级市场股价走势受多方面因素综合作用，敬请广大 投资者理性看待市场波动，注意投资风险。 ...